Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • RRMS

    - PMLiVE

    North East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adults

    In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, providing...

    Healthinote (by Cognitant)

    - PMLiVE

    Bridging the gap in personalised digital support: My Stroke Companion

    To empower stroke survivors to engage with their care, Cognitant, in partnership with University College London Hospitals (UCLH), identified a need for a new digital health companion that can support...

    Healthinote (by Cognitant)

    - PMLiVE

    Kidney Research UK invests in Healthinote patient education platform which could support >15m people with long term health conditions

    Kidney Research UK, the leading charity dedicated to kidney health, has made a significant investment in Cognitant Group Ltd, a leading provider of digital education and support tools to improve...

    Healthinote (by Cognitant)

    - PMLiVE

    Health literacy & the creation of shared decision aids for patients with cancer

    In this blog, Gini Melesi, Head of Transformation, East of England Cancer Alliance, & Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust, explore the relationship between...

    Healthinote (by Cognitant)

    - PMLiVE

    Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

    The immune-mediated disease affects more than 2.9 million people worldwide

    - PMLiVE

    Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

    The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    - PMLiVE

    Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

    The neurological disorder affects approximately 2.9 million people globally

    - PMLiVE

    Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS

    Tolebrutinib is currently being evaluated in various forms of the neurological disorder

    - PMLiVE

    Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

    The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links